Syn Ake Powder

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of syn ake powder in China. Welcome to wholesale bulk high quality syn ake powder for sale here from our factory. Good service and reasonable price are available.

Syn Ake Powder, INCI name Dipeptide Diaminobutyroyl Benzylamide Diacetate, is a widely used biomimetic cosmetic peptide raw material. Mimicking the active principle of temple viper venom, it relaxes facial muscle contraction to smooth expression lines, crow's feet and forehead wrinkles. The powder features excellent water solubility, easy to formulate into serums, creams and other skincare products. As a professional peptide supplier, peptide provides high purity Syn Ake Powder with sample and bulk supply available, full COA & TDS documents to support cosmetic R&D and manufacturing.

Certificate of Analysis
Compound name	Dipeptide diaminobutyroyl benzylamide diacetate
Grade	Pharmaceutical grade
CAS No.	823202-99-9
Quantity	18g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202601090085
MFG	Jan 9th 2026
EXP	Jan 8th 2029
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.85%
Loss on drying	≤1.0%	0.32%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.63%
Single impurity	<0.8%	0.57%
Total microbial count	≤750cfu/g	533
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	577ppm
Storage	Store in a sealed, dark, and dry place below -20°C

In the niche market of neurotransmitter-regulated anti-aging peptides, Syn Ake Powder is not an isolated active molecule, but rather, together with ingredients such as Argireline (acetyl hexapeptide-8), Leuphasyl (pentapeptide-18), SNAP-8 (acetyl hexapeptide-3), and Matrixyl 3000 (palmitoyl pentapeptide-4), to form the "botulinum toxin-like" and signaling peptide matrix within the cosmetic ingredient market. However, upon in-depth analysis of molecular topology, receptor-binding kinetics, signal transduction pathways, and bioavailability, SYN-AKE demonstrates significant differentiated advantages in terms of precision of its mechanism of action, potency of efficacy, and safety profile.

Specificity of the Target and Differences in Receptor Binding Kinetics
SYN-AKE's core competitive advantage stems from its highly specific targeting ability of nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (NMJ). nAChRs belong to the ligand-gated ion channel superfamily; functional receptors typically adopt a pentameric structure composed of α2βγδ (fetal type) or α2βεδ (adult type) subunits. The molecular design of SYN-AKE was inspired by the Waglerin-1 protein found in the venom of the Malaysian mangrove viper (Trimeresurus wagleri), whose amino acid sequence {beta-Ala}-Pro-{Dab-NHBzl} spatially mimics the key active fragment of Waglerin-1, enabling it to precisely recognize and bind to a specific binding site on the ε subunit (the γ subunit in the fetal type) of nAChR.

This binding follows a competitive antagonistic mechanism: SYN-AKE competes with acetylcholine (ACh) for the binding site on the receptor; however, upon binding, it does not induce a conformational change in the ion channel. Instead, it locks the receptor in the closed state, preventing the transmembrane flow of sodium ions (Na⁺) and potassium ions (K⁺), thereby inhibiting the depolarization of the postsynaptic membrane and blocking the generation and conduction of action potentials. In contrast, the mechanism of action of Argireline (acetyl hexapeptide-8), whose sequence is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂, is entirely different. It primarily mimics the N-terminal sequence of the SNAP-25 protein in the SNARE complex (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor), competitively binds to syntaxin and VAMP/synaptobrevin,

disrupting the assembly of the SNARE complex, thereby inhibiting the fusion of synaptic vesicles with the presynaptic membrane and reducing the release of ACh. In other words, SYN-AKE acts on the receptor end of the postsynaptic membrane to directly block signal reception, while Argireline acts on the release end of the presynaptic membrane to indirectly reduce signal transmission. From a pharmacological perspective, the action of postsynaptic receptor antagonism is more direct, rapid, and controllable, whereas presynaptic release inhibition involves feedback regulatory mechanisms that may lead to compensatory increases in release, affecting the stability of long-term efficacy.Leuphasyl (pentapeptide-18) has a mechanism of action similar to Argireline, but its sequence is Tyr-D-Ala-Gly-Phe-Leu. It primarily mimics the structure of endorphins and regulates neuropeptide release by activating opioid receptors;

its pathway of action is more indirect, and its potency is relatively weaker. SNAP-8 (acetyl octapeptide-3) is an extended analog of Argireline that enhances efficacy by increasing binding affinity to the SNARE complex; however, it remains subject to the inherent limitations of presynaptic mechanisms of action. Matrixyl 3000 (palmitoyl pentapeptide-4) belongs to the category of signaling peptides. Its primary function is to promote collagen and fibronectin synthesis in fibroblasts by activating the TGF-β signaling pathway, thereby facilitating structural reconstruction of the dermis rather than regulating signaling at the neuromuscular junction. Consequently, its mechanism of action is entirely different from that of SYN-AKE in terms of immediate wrinkle reduction and the improvement of dynamic wrinkles.

The molecular design of Syn Ake Powder incorporates multiple non-natural amino acid modifications, which represent a key advantage in terms of stability compared to other linear peptides.

First, the N-terminal β-alanine (β-Ala) is a non-proteinogenic amino acid. Compared to conventional α-amino acids, the introduction of β-Ala alters the main-chain conformation of the peptide, increasing the molecule's rigidity and making it more difficult for endogenous aminopeptidases to recognize and cleave it. Second, the Dab (diaminobutyric acid) residue in the sequence has been modified via benzylamidation (Dab-NHBzl); this modification not only mimics the key pharmacophore in natural Waglerin-1 but also protects the peptide bond from hydrolytic attack by endopeptidases through steric hindrance.

Furthermore, Syn Ake Powder exists in the form of a diacetate; the introduction of the acetate group enhances the molecule's water solubility and crystalline stability, enabling it to exhibit excellent chemical inertness in both solid-state storage and liquid formulations.
In contrast, although linear peptides such as Argireline have also undergone N-terminal acetylation and C-terminal amidation to enhance stability, their main chains are still composed of conventional L-type α-amino acids, making them susceptible to degradation by various peptidases in vivo (such as aminopeptidases, carboxypeptidases, and endopeptidases), resulting in a relatively short half-life.

Although D-alanine (D-Ala) has been introduced into Leuphasyl to enhance metabolic resistance, its overall sequence is short, and its binding affinity is limited. SYN-AKE's non-natural amino acid modification strategy confers greater enzymatic resistance and conformational stability at the molecular level, enabling it to maintain a longer window of activity in the skin microenvironment and thereby deliver more sustained efficacy.

[1]Gok, B., Budama-Kilinc, Y., & Kecel-Gunduz, S. (2024). Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests. Journal of Biomolecular Structure and Dynamics, 42(10), 5015–5029. 

[2]Debono, J., Xie, B., Violette, A., Fourmy, R., Jaeger, M., & Fry, B. G. (2017). Viper venom botox: The molecular origin and evolution of the waglerin peptides used in anti-wrinkle skin cream. Journal of Molecular Evolution, 84(1), 8–11.

[3]Zhu, M., He, X., Zhu, Z., & Li, Y. (2026). The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. International Journal of Cosmetic Science. 

[4]Schagen, S. K. (2017). Topical peptide treatments with effective anti-aging results. Cosmetics, 4(2), 16. 

[5]Ferreira, M. S., Magalhães, M. C., Sousa-Lobo, J. M., & Almeida, I. F. (2020). Trending anti-aging peptides. Cosmetics, 7(3), 58.

Hot Tags: syn ake powder, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale